AB Corporate is trading at 36.29 as of the 30th of November 2024. This is a 0.50 percent increase since the beginning of the trading day. The etf's lowest day price was 36.29. AB Corporate has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for AB Corporate Bond are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Eyegate Pharmaceuticals, Inc. The company has 7.1 M outstanding shares of which 54.54 K shares are currently shorted by private and institutional investors with about 0.02 trading days to cover. More on AB Corporate Bond
AB Corporate Bond [EYEG] is traded in USA and was established null. The fund is listed under Corporate Bond. The entity is thematically classified as Corporate ETFs. AB Corporate Bond currently have in assets under management (AUM).
AB Corporate Bond currently holds about 3.66 M in cash with (8.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check AB Corporate Probability Of Bankruptcy
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AB Corporate. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
When determining whether AB Corporate Bond is a strong investment it is important to analyze AB Corporate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AB Corporate's future performance. For an informed investment choice regarding EYEG Etf, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in AB Corporate Bond. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
The market value of AB Corporate Bond is measured differently than its book value, which is the value of EYEG that is recorded on the company's balance sheet. Investors also form their own opinion of AB Corporate's value that differs from its market value or its book value, called intrinsic value, which is AB Corporate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AB Corporate's market value can be influenced by many factors that don't directly affect AB Corporate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AB Corporate's value and its price as these two are different measures arrived at by different means. Investors typically determine if AB Corporate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AB Corporate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.